GZ-793A

立即咨询

GZ-793A

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1356447-90-9

包装与价格：

包装	价格(元)
100mg	电议
250mg	电议
500mg	电议

产品介绍

GZ-793A 是一种具有口服活性和选择性的囊泡单胺转运体-2 (VMAT2) 抑制剂，其K_i值为 0.029 μM。GZ-793A 能抑制甲基苯丙胺 (METH) 诱导的多巴胺释放，可用于 METH 成瘾研究。

生物活性

GZ-793A is an orally active and selectivevesicular monoamine transporter-2 (VMAT2)inhibitor, with anK_iof 0.029 μM. GZ-793A inhibits the neurochemical effects of methamphetamine (METH)-induced dopamine release. GZ-793A can be used for research of METH addiction^[1]^[2]^[3].

IC₅₀& Target

Ki: 0.029 μM (VMAT2)^[1].

体内研究
(In Vivo)

GZ-793A (30, 60, 120 or 240 mg/kg; p.o.; once) decreases the number of METH infusions self-administered across each time interval evaluats in a dose-dependent manner^[1].
GZ-793A (1-100 μM; 90 min) inhibits METH (5 μM)-evoked fractional dopamine releases^[2].

Animal Model:	Adult male Sprague-Dawley rats^[1].
Dosage:	30, 60, 120 or 240 mg/kg
Administration:	Oral administration; once.
Result:	Decreased the number of METH infusions self-administered in a dose-dependent manner, and with an ~85% reduction at the highest dose (240 mg/kg). Decreased the METH self-administration produced by lasted at least 180 min.

Animal Model:	Male Sprague-Dawley rats (250–275 g; 9-week-old; 0.5 mm thick rats coronal striatal slices are used)^[2].
Dosage:	1-100 μM
Administration:	90 min
Result:	Inhibited methamphetamine-evoked dopamine released in a concentration-dependent manner.

分子量

464.04

Formula

C₂₆H₃₈ClNO₄

CAS 号

1356447-90-9

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.